The Moderna share price: have I missed the boat?

After rallying over 300% in the past year, Jonathan Smith offers his opinion on whether the Moderna share price still offers value.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The impact of the Covid-19 pandemic has been felt in many ways over the past year. In the stock market, it was the trigger for the market crash of March 2020. However, some stocks have seen a rising share price associated with the virus. One example is the Moderna (NASDAQ: MRNA) share price, that’s up over 300% over the past year. This is largely thanks to the vaccine development. After such a stellar run, the question is whether I’ve missed the boat to buy now.

The story behind the rally

Moderna was a well known US-based company even before the pandemic hit. It went public in 2018, and became the largest biotech IPO in history with a valuation of $7.5bn. 

Despite the lofty valuation, the Moderna share price traded quite flat after going public. In my experience, this is the case with drug discovery and development companies. When FDA approval comes through, or a drug reaches commercial viability, the share price often rockets higher. Before this point, high research costs can burden the company.

For Moderna, it jumped on the opportunity to help with finding a vaccine for Covid-19. This progress started in March last year, coinciding with the start of the rally in the share price. 

The price spiked further in November, when the vaccine (mRNA-1273) showed a 94% efficacy rate. The subsequent green light given for distribution, not only in the US but in other countries, continued to support the rally into 2021.

Over the past month, the share price has trod water around the $130 mark. This is down from the highs above $170 seen a few months back, but at the same time is a substantial increase from where it traded a year ago.

My outlook for the Moderna share price

In my opinion, Moderna are doing all the right things at the moment. The vaccine has even reached us in the UK, with it being offered out this week. The company is planning on supplying up to 1bn doses globally this year.

However, what about the finances? For 2020 revenue was $803m compared to $60m in 2019. However, due to high research and development costs, Moderna recorded a loss of $747m.

In my opinion, a lot of investors are buying the stock for speculative purposes. Fundamentally, I don’t see the business as being worth the current valuation of over $50bn. I understand high losses in 2020 may be reduced in 2021 now that it has the vaccine, but even then, I don’t see the numbers stacking up.

As an investor, I want to be able to see a future where stable and strong profits are generated. This is one of the key boxes that Moderna doesn’t tick for me, so I won’t be buying.

This isn’t to say that the Moderna share price can’t rally higher this year, indeed I think buyers will drive the price higher. But as a long-term investor, I don’t see this being supported in years to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

jonathansmith1 has no position in any of the shares mentioned. The Motley Fool UK has recommended Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

If I’d invested £20,000 in the FTSE 250 at the start of 2024, here’s what I’d have now

The FTSE 250 has been in growth mode this year. Our writer weighs some pros and cons of investing in…

Read more »

Investing Articles

Is the Rolls-Royce share price about to go nuclear?

This writer wonders whether excitement about Rolls-Royce's small modular reactor (SMR) business could push the share price even higher.

Read more »